Cost-Effectiveness Analysis of Hypertension Treatment: Controlled Release Nifedipine and Candesartan Low-Dose Combination Therapy in Patients with Essential Hypertension-The Nifedipine and Candesartan Combination (NICE-Combi) Study-
Authors:
- 1 January 2005
- journal article
- research article
- Published by Japanese Society of Hypertension in Hypertension Research
- Vol. 28 (7) , 585-591
Abstract
Societal interest in pharmaco-economic analysis is increasing in Japan. In this study, the cost-effectiveness of low-dose combination therapy with controlled release nifedipine plus candesartan and up-titrated monotherapy with candesartan was estimated, based on the results of the NICE-Combi study. The NICE-Combi study was a double-blind, parallel arm, randomized clinical trial to compare the efficacy of low-dose combination therapy of controlled release nifedipine (20 mg/day) plus candesartan (8 mg/day) vs. up-titrated monotherapy of candesartan (12 mg/day) on blood pressure control in Japanese patients with mild to severe essential hypertension who were not sufficiently controlled by the conventional dose of candesartan (8 mg/day). The incremental cost effectiveness of each cohort during the 8-week randomization period was compared, from the perspective of a third-party payer (i.e., insurers). The average total cost per patient was 29,943 Japanese yen for the combination therapy group and 33,182 Japanese yen for the candesartan monotherapy group, while the rate of achievement of the target blood pressure was significantly higher in the combination therapy group than in the up-titrated monotherapy group. In the combination therapy group, higher efficacy and lower incremental treatment cost (“Dominance”) were observed when compared to the monotherapy group. The sensitivity analyses also supported the results. In conclusion, these results suggest that combination therapy with controlled release nifedipine and low-dose candesartan (8 mg) is “dominant” to up-titrated candesartan monotherapy for the management of essential hypertension. This conclusion was robust to sensitivity analysis.Keywords
This publication has 10 references indexed in Scilit:
- Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) StudyJournal Of Hypertension, 2005
- Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialThe Lancet, 2004
- Comparison of Nifedipine Retard with Angiotensin Converting Enzyme Inhibitors in Japanese Hypertensive Patients with Coronary Artery Disease: The Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) Randomized TrialHypertension Research, 2004
- Nifedipine Retard Was as Effective as Angiotensin Converting Enzyme Inhibitors in Preventing Cardiac Events in High-Risk Hypertensive Patients with Diabetes and Coronary Artery Disease: The Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) Subgroup AnalysisHypertension Research, 2004
- 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertensionJournal Of Hypertension, 2003
- 2003 European Society of Hypertension???European Society of Cardiology guidelines for the management of arterial hypertension*Journal Of Hypertension, 2003
- The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureThe JNC 7 ReportJAMA, 2003
- Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2002
- Guidelines for the Management of Hypertension for General Practitioners.Hypertension Research, 2001
- Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical EventsCirculation, 2000